First-in-human trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13537
Abstract: Soluble guanylate cyclase (sGC) and its product, cyclic guanosine monophosphate play a role in learning and memory formation. Zagociguat (CY6463) is a novel stimulator of sGC being developed for the treatment of neurodegenerative disease. Single… read more here.
Keywords: stimulator; cyclase; cns; zagociguat cy6463 ... See more keywords